Pretreatment with ticagrelor may offset additional inhibition of platelet and coagulation activation with bivalirudin compared to heparin during primary percutaneous coronary intervention.

[1]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[2]  E. Braunwald,et al.  Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial , 2017, Journal of the American Heart Association.

[3]  C. Held,et al.  Bivalirudin versus Heparin Monotherapy in Myocardial Infarction , 2017, The New England journal of medicine.

[4]  J. Garot,et al.  Bivalirudin infusion to reduce ventricular infarction: the open-label, randomised Bivalirudin Infusion for Ventricular InfArction Limitation (BIVAL) study. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  N. Zhang,et al.  Circulating soluble P-selectin must dimerize to promote inflammation and coagulation in mice. , 2017, Blood.

[6]  H. Hemker,et al.  Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate? , 2016, Journal of the American Heart Association.

[7]  G. Andersen,et al.  Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction , 2015, Thrombosis Journal.

[8]  P. Jüni,et al.  Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[9]  G. Stone,et al.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. , 2015, JAMA.

[10]  Mike Fisher,et al.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial , 2014, The Lancet.

[11]  A. Farcomeni,et al.  Platelet activation is associated with myocardial infarction in patients with pneumonia. , 2014, Journal of the American College of Cardiology.

[12]  L. Faxälv,et al.  Thrombin-induced platelet activation via PAR4: pivotal role for exosite II , 2014, Thrombosis and Haemostasis.

[13]  J. Badimón,et al.  Pathophysiology of Acute Coronary Syndrome , 2014, Current Atherosclerosis Reports.

[14]  J. Sidaway,et al.  Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1 , 2014, Journal of cardiovascular pharmacology and therapeutics.

[15]  G. Andersen,et al.  IL-6 signalling in patients with acute ST-elevation myocardial infarction. , 2014, Results in immunology.

[16]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[17]  A. Jeppsson,et al.  Sampling conditions influence multiple electrode platelet aggregometry in cardiac surgery patients , 2013, Scandinavian cardiovascular journal : SCJ.

[18]  H. Hamm,et al.  Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation , 2013, Journal of Thrombosis and Thrombolysis.

[19]  M. Pansieri,et al.  High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. , 2011, Journal of the American College of Cardiology.

[20]  A. Weintraub,et al.  Bivalirudin Is a Dual Inhibitor of Thrombin and Collagen-Dependent Platelet Activation in Patients Undergoing Percutaneous Coronary Intervention , 2011, Circulation. Cardiovascular interventions.

[21]  L. Bonello,et al.  Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy , 2010, Platelets.

[22]  A. Kastrati,et al.  Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement , 2010, Journal of thrombosis and haemostasis : JTH.

[23]  Mark J. Antonino,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[24]  M. Ray,et al.  A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  A. Kaider,et al.  Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. , 2009, European heart journal.

[26]  A. Kastrati,et al.  Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention , 2009, Thrombosis and Haemostasis.

[27]  A. Kastrati,et al.  Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. , 2008, European heart journal.

[28]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[29]  Samin K. Sharma,et al.  Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. , 2007, The American journal of cardiology.

[30]  W. Hermens,et al.  Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[31]  B. Sobel,et al.  Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation , 2006, Coronary artery disease.

[32]  H. Yip,et al.  Levels and value of soluble P-selectin following acute myocardial infarction: evaluating the link between soluble P-selectin levels and recruitment of circulating white blood cells and the marker for the rapid diagnosis of chest pain. , 2005, Chang Gung medical journal.

[33]  R. Storey,et al.  Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin. , 2005, Thrombosis Research.

[34]  S. Kunapuli,et al.  Central role of the P2Y12 receptor in platelet activation. , 2004, The Journal of clinical investigation.

[35]  D. Kereiakes,et al.  Soluble P-selectin Is Not a Surrogate Marker for Platelet P-selectin: Evidence from a Multicenter Chest Pain Study Group , 2004, Journal of Thrombosis and Thrombolysis.

[36]  Gregory Y H Lip,et al.  The adhesion molecule P-selectin and cardiovascular disease. , 2003, European heart journal.

[37]  J. Kvasnička,et al.  Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. , 2003, Physiological research.

[38]  C. Foster,et al.  Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. , 2002, Blood.

[39]  R. Shebuski,et al.  Role of inflammatory mediators in thrombogenesis. , 2002, The Journal of pharmacology and experimental therapeutics.

[40]  M. Hori,et al.  Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. , 1998, Circulation.

[41]  H. Shimomura,et al.  Serial changes in plasma levels of soluble P-selectin in patients with acute myocardial infarction. , 1998, The American journal of cardiology.

[42]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[43]  U. Ikeda,et al.  Adenosine stimulates nitric oxide synthesis in vascular smooth muscle cells. , 1997, Cardiovascular research.